Dr. Bhaskar Kante

OP Timings

Profile

Dr. Bhaskar Kante is a highly skilled gastroenterologist in Hyderabad, specializing in interventional gastroenterology and hepatology.

As a key member of KAGE – KIMS Advanced Gastroenterology and Endoscopy at KIMS Hospitals, Secunderabad, he provides expert care for a wide range of digestive and liver disorders.

With advanced training in medical gastroenterology, 13+ years of experience, and a prestigious Fellowship in Inflammatory Bowel Disease (IBD) from AIIMS, Dr. Kante has a special interest in managing complex IBD cases, Crohn’s disease, and ulcerative colitis.

His expertise also includes treating GERD, IBS, liver cirrhosis, fatty liver disease, pancreatitis, and gastrointestinal cancers.

Renowned as one of the best gastroenterologists in Hyderabad, Dr. Kante is proficient in advanced therapeutic endoscopic procedures, including ERCP, endoscopic ultrasound (EUS), and endoscopic management of GI bleeding and strictures.

His minimally invasive approach ensures precise diagnosis and effective treatment for complex digestive conditions.

At KIMS Hospitals, Secunderabad, Dr. Kante plays a crucial role in KAGE – KIMS Advanced Gastroenterology and Endoscopy, a center known for cutting-edge gastroenterology treatments.

His clinical expertise, research-driven approach, and commitment to patient care make him a sought-after gastro doctor in Hyderabad.

For advanced treatment of gastrointestinal and liver conditions, consult Dr. Bhaskar Kante at KIMS Hospitals, Secunderabad today.

Publications & Research Papers

• Efficacy and tolerability of Hyperbaric oxygen therapy in stricturing Crohn’s disease: Intestinal Research Journal 2021
• Monotherapy with Thiopurines in Stricturing Crohn’s Disease: A real-life experience from low and middle-income countries. Published in: Indian Journal of Gastroenterology 2022
• Fecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: A randomized controlled trial. Published in Gut Journal July 2022
• Real-world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease: Published in Nature Scientific Reports 2021
• Role of EUS in idiopathic ulcerative colitis: Published in EUS Journal 2021
• Correlation of EUS anorectum with disease activity in ulcerative colitis: Poster Presentation in ISGCON 2016 New Delhi
• Can EUS differentiate clinically active Ulcerative colitis: Poster Presentation DDW San Diego 2016
• Efficacy and tolerability of Hyperbaric oxygen therapy in stricturing Crohn’s disease: Poster Presentation AOCC 2020
• Anti-tubercular treatment given to differentiate Crohn’s disease from Intestinal tuberculosis predisposes to stricture formation: Published in Journal of Crohn’s Colitis 2021
• Randomized clinical trial: Exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis: Published in Alimentary Pharmacology and Therapeutics 2021
• Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease: Published in Intestinal Research Journal 2020
• Extra esophageal presentation of GERD chapter in the book titled Gastroesophageal reflux disease
• Case Presentation: IBD and PSC difficult-to-treat case in ECCO 2019, New Delhi
• Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with IBD on anti-TNF therapy in tuberculosis regions: Published in Alimentary Pharmacology and Therapeutics 2022
• Minimal risk of lymphoma and nonmelanoma skin cancer despite long-term use of Thiopurines in patients with IBD: A longitudinal cohort analysis from northern India: Published in Journal of Gastroenterology and Hepatology 2022
• Real-world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease: Published in Nature Scientific Reports 2021
• Poster presentation DDW 2022: ‘SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS’